

1. *Drug-eluting stents: a study of international practice*
Austin, D., et al.
Am Heart J, 2009. **158**(4): p. 576-84.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19781417
2. *The effect of intended duration of clopidogrel use on early and late mortality and major adverse cardiac events in patients with drug-eluting stents*
Butler, M.J., et al.
Am Heart J, 2009. **157**(5): p. 899-907.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19376319
3. *Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angioplasty (PASEO) randomized trial*
Di Lorenzo, E., et al.
Am Heart J, 2009. **158**(4): p. e43-50.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19781402
4. *Optical coherence tomography patterns of stent restenosis*
Gonzalo, N., et al.
Am Heart J, 2009. **158**(2): p. 284-93.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19619707
5. *Incidence of stent thrombosis and adverse cardiac events 5 years after sirolimus stent implantation in clinical practice*
Goy, J.J., et al.
Am Heart J, 2009. **157**(5): p. 883-8.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19376316
6. *Clinical and angiographic comparison of everolimus-eluting and paclitaxel-eluting stents in small coronary arteries: a post hoc analysis of the SPIRIT III randomized trial*
Hermiller, J.B., et al.
Am Heart J, 2009. **158**(6): p. 1005-10.
<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation>

n&list_uids=19958868

7. *Patterns of use of thienopyridine therapy after percutaneous coronary interventions with drug-eluting stents and bare-metal stents*
Ko, D.T., et al.
Am Heart J, 2009. **158**(4): p. 592-598 e1.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19781419
8. *Stent thrombosis up to 3 years after stenting for ST-segment elevation myocardial infarction versus for stable angina--comparison of the effects of drug-eluting versus bare-metal stents*
Leibundgut, G., et al.
Am Heart J, 2009. **158**(2): p. 271-6.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19619705
9. *High-intensity interval training may reduce in-stent restenosis following percutaneous coronary intervention with stent implantation A randomized controlled trial evaluating the relationship to endothelial function and inflammation*
Munk, P.S., et al.
Am Heart J, 2009. **158**(5): p. 734-41.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19853690
10. *Relationship between severity of renal impairment and 2-year outcomes after sirolimus-eluting stent implantation*
Ota, T., et al.
Am Heart J, 2009. **158**(1): p. 92-8.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19540397
11. *Three-year clinical outcome after primary stenting of totally occluded native coronary arteries: a randomized comparison of bare-metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (Primary Stenting of Totally Occluded Native Coronary Arteries [PRISON] II study)*
Rahel, B.M., et al.
Am Heart J, 2009. **157**(1): p. 149-55.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19540397

n&list_uids=19081412

12. *Drug-eluting versus bare-metal stents for treating saphenous vein grafts*
Shishehbor, M.H., et al.
Am Heart J, 2009. **158**(4): p. 637-43.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19781425

13. *Vitamin K epoxide reductase complex subunit 1 gene polymorphism is associated with atherothrombotic complication after drug-eluting stent implantation: 2-Center prospective cohort study*
Suh, J.W., et al.
Am Heart J, 2009. **157**(5): p. 908-12.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19376320

14. *Relationship between neointimal coverage of sirolimus-eluting stents and lesion characteristics: a study with serial coronary angiography*
Yamamoto, M., et al.
Am Heart J, 2009. **158**(1): p. 99-104.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19540398

15. *Comparison of outcomes of drug-eluting stents versus bare-metal stents in nonostial proximal left anterior descending coronary arteries*
Bonello, L., et al.
Am J Cardiol, 2009. **103**(4): p. 496-500.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19195509

16. *Timing, causes, and predictors of death after three years' follow-up in the Danish Multicenter Randomized Study of Fibrinolysis versus Primary Angioplasty in Acute Myocardial Infarction (DANAMI-2) trial*
Busk, M., et al.
Am J Cardiol, 2009. **104**(2): p. 210-5.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19576349

17. *Classification and potential mechanisms of intravascular ultrasound patterns of stent fracture*

Doi, H., et al.

Am J Cardiol, 2009. **103**(6): p. 818-23.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19268738

18. *Relation of troponin I levels following nonemergent percutaneous coronary intervention to short- and long-term outcomes*

Feldman, D.N., et al.

Am J Cardiol, 2009. **104**(9): p. 1210-5.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19840564

19. *Racial disparities in outcomes following percutaneous coronary intervention with drug-eluting stents*

Gaglia, M.A., Jr., et al.

Am J Cardiol, 2009. **103**(5): p. 653-8.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19231328

20. *Antiplatelet therapy in patients with anticoagulants undergoing percutaneous coronary stenting (from STENTing and oral antiCOagulants [STENTICO])*

Gilard, M., et al.

Am J Cardiol, 2009. **104**(3): p. 338-42.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19616664

21. *Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis*

Giusti, B., et al.

Am J Cardiol, 2009. **103**(6): p. 806-11.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19268736

22. *Comparison of long-term efficacy of the paclitaxel-eluting stent versus the bare-metal stent for treatment of unprotected left main coronary artery disease*

Han, Y., et al.

Am J Cardiol, 2009. **103**(2): p. 194-8.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19121435

23. *Comparison of long-term outcomes of bare metal or drug-eluting stent implantation in standard versus off-label coronary narrowings*
Harjai, K.J., et al.
Am J Cardiol, 2009. **103**(11): p. 1537-45.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19463512

24. *Serial intravascular ultrasound analysis of peri-stent remodeling and proximal and distal edge effects after sirolimus-eluting or paclitaxel-eluting stent implantation in patients with diabetes mellitus*
Jensen, L.O., et al.
Am J Cardiol, 2009. **103**(8): p. 1083-8.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19361594

25. *Paclitaxel-eluting stent long-term outcomes in percutaneous saphenous vein graft interventions (PELOPS) study*
Jim, M.H., et al.
Am J Cardiol, 2009. **103**(2): p. 199-202.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19121436

26. *Impact of different re-stenting strategies on expansion of a drug-eluting stent implanted to treat bare-metal stent restenosis*
Kalinczuk, L., et al.
Am J Cardiol, 2009. **104**(4): p. 531-7.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19660607

27. *Comparison of long versus short ("spot") drug-eluting stenting for long coronary stenoses*
Katritsis, D.G., et al.
Am J Cardiol, 2009. **104**(6): p. 786-90.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19733712

28. *Three-year survival following multivessel percutaneous coronary intervention with bare-metal or drug-eluting stents in unselected patients*
Kukreja, N., et al.
Am J Cardiol, 2009. **103**(2): p. 203-11.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19463512

n&list_uids=19121437

29. *Optical coherence tomographic results at six-month follow-up evaluation of the CATANIA coronary stent system with nanothin Polyzene-F surface modification (from the Assessment of The LAtest Non-Thrombogenic Angioplasty Stent [ATLANTA] trial)*

La Manna, A., et al.

Am J Cardiol, 2009. **103**(11): p. 1551-5.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19463514

30. *Two-year results of paclitaxel-eluting stents in patients with medically treated diabetes mellitus from the TAXUS ARRIVE program*

Lasala, J.M., et al.

Am J Cardiol, 2009. **103**(12): p. 1663-71.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19539073

31. *Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction*

Lee, C.W., et al.

Am J Cardiol, 2009. **104**(10): p. 1370-6.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19892052

32. *Prognostic value of hemoglobin A1C levels in patients with diabetes mellitus undergoing percutaneous coronary intervention with stent implantation*

Lemesle, G., et al.

Am J Cardiol, 2009. **104**(1): p. 41-5.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19576319

33. *An integrated TAXUS IV, V, and VI intravascular ultrasound analysis of the predictors of edge restenosis after bare metal or paclitaxel-eluting stents*

Liu, J., et al.

Am J Cardiol, 2009. **103**(4): p. 501-6.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19195510

34. *Comparison of the sirolimus-eluting versus paclitaxel-eluting coronary stent in*

patients with diabetes mellitus: the diabetes and drug-eluting stent (DiabeDES) randomized angiography trial

Maeng, M., et al.

Am J Cardiol, 2009. **103**(3): p. 345-9.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19166687

35. *One-year outcomes from the TAXUS express stent versus cypher stent*

Mayor, M., et al.

Am J Cardiol, 2009. **103**(7): p. 930-6.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19327418

36. *Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry)*

Nienaber, C.A., et al.

Am J Cardiol, 2009. **104**(10): p. 1362-9.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19892051

37. *Relation of drug-eluting stent strut distribution to stent thrombosis in coronary arteries*

Opolski, M.P., et al.

Am J Cardiol, 2009. **104**(3): p. 343-8.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19616665

38. *Association of a unique cardiovascular risk profile with outcomes in Hispanic patients referred for percutaneous coronary intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry)*

Parikh, S.V., et al.

Am J Cardiol, 2009. **104**(6): p. 775-9.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19733710

39. *Prognostic influence of diabetes mellitus on long-term clinical outcomes and stent thrombosis after drug-eluting stent implantation in asian patients*

Park, D.W., et al.

Am J Cardiol, 2009. **103**(5): p. 646-52.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19231327

40. *Effectiveness of primary percutaneous coronary interventions for stent thrombosis*
Parodi, G., et al.
Am J Cardiol, 2009. **103**(7): p. 913-6.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19327415

41. *Comparison of six-month outcomes for primary percutaneous revascularization for acute myocardial infarction with drug-eluting versus bare metal stents (from the APEX-AMI study)*
Patel, M.R., et al.
Am J Cardiol, 2009. **103**(2): p. 181-6.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19121433

42. *Major adverse cardiac events at follow-up after bare-metal stenting versus drug-eluting stenting in ST-elevated myocardial infarction*
Pierre-Louis, B., et al.
Am J Cardiol, 2009. **103**(12): p. 1672-4.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19539074

43. *Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis*
Pinto Slottow, T.L., et al.
Am J Cardiol, 2009. **104**(4): p. 525-30.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19660606

44. *A qualitative and quantitative angiographic analysis of stent fracture late following sirolimus-eluting stent implantation*
Popma, J.J., et al.
Am J Cardiol, 2009. **103**(7): p. 923-9.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19327417

45. *Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention*
Price, M.J., et al.

Am J Cardiol, 2009. **103**(10): p. 1339-43.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19427425

46. *Temporal relation between Clopidogrel cessation and stent thrombosis after drug-eluting stent implantation*

Roy, P., et al.

Am J Cardiol, 2009. **103**(6): p. 801-5.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19268735

47. *Outcome differences with the use of drug-eluting stents for the treatment of in-stent restenosis of bare-metal stents versus drug-eluting stents*

Steinberg, D.H., et al.

Am J Cardiol, 2009. **103**(4): p. 491-5.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19195508

48. *Comparison of drug-eluting stents and bare-metal stents for the treatment of unprotected left main coronary artery disease in acute coronary syndromes*

Tamburino, C., et al.

Am J Cardiol, 2009. **103**(2): p. 187-93.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19121434

49. *Effectiveness of two-year clopidogrel + aspirin in abolishing the risk of very late thrombosis after drug-eluting stent implantation (from the TYCOON [two-year CLOpidOgrel need] study)*

Tanzilli, G., et al.

Am J Cardiol, 2009. **104**(10): p. 1357-61.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19892050

50. *Timing of noncardiac surgery after coronary artery stenting with bare metal or drug-eluting stents*

van Kuijk, J.P., et al.

Am J Cardiol, 2009. **104**(9): p. 1229-34.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19840567

51. *Comparison of neointimal hyperplasia with drug-eluting stents versus bare metal stents in patients undergoing intracoronary bone-marrow mononuclear cell transplantation following acute myocardial infarction*
Villa, A., et al.
Am J Cardiol, 2009. **103**(12): p. 1651-6.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19539071
52. *Outcome of patients treated by a novel thin-strut cobalt-chromium stent in the drug-eluting stent era: Results of the SKICE (Skylor in real world practice) registry*
Burzotta, F., et al.
Catheter Cardiovasc Interv, 2009. **73**(4): p. 457-65.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19229977
53. *Long-term clinical benefit of drug-eluting stents over bare-metal stents in diabetic patients with de novo left main coronary artery disease: results from a real-world multicenter registry*
Capodanno, D., et al.
Catheter Cardiovasc Interv, 2009. **73**(3): p. 310-6.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19214964
54. *Angiographic and clinical outcomes of drug-eluting versus bare metal stent deployment in the Occluded Artery Trial*
Dzavik, V., et al.
Catheter Cardiovasc Interv, 2009. **73**(6): p. 771-9.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19309733
55. *Outcomes after percutaneous coronary intervention of ostial lesions in the era of drug-eluting stents*
Freeman, M., et al.
Catheter Cardiovasc Interv, 2009. **73**(6): p. 763-8.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19309731
56. *Defining a new standard for IVUS optimized drug eluting stent implantation: the PRAVIO study*
Gerber, R.T., et al.

Catheter Cardiovasc Interv, 2009. **74**(2): p. 348-56.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19213067

57. *Analysis of left main coronary artery bifurcation lesions treated with biolimus-eluting DEVAX AXXESS plus nitinol self-expanding stent: intravascular ultrasound results of the AXXENT trial*

Hasegawa, T., et al.

Catheter Cardiovasc Interv, 2009. **73**(1): p. 34-41.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19089934

58. *Impact of a prolonged delivery inflation time for optimal drug-eluting stent expansion*

Kawasaki, T., et al.

Catheter Cardiovasc Interv, 2009. **73**(2): p. 205-11.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19085915

59. *The incidence and predictors of postprocedural incomplete stent apposition after angiographically successful drug-eluting stent implantation*

Kim, Y.S., et al.

Catheter Cardiovasc Interv, 2009. **74**(1): p. 58-63.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19360868

60. *Gender-based evaluation of the XIENCE V everolimus-eluting coronary stent system: clinical and angiographic results from the SPIRIT III randomized trial*

Lansky, A.J., et al.

Catheter Cardiovasc Interv, 2009. **74**(5): p. 719-27.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19530147

61. *Multicenter international registry of unprotected left main coronary artery percutaneous coronary intervention with drug-eluting stents in patients with myocardial infarction*

Lee, M.S., et al.

Catheter Cardiovasc Interv, 2009. **73**(1): p. 15-21.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19089930

62. *Randomized evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year results of the PAINT trial*
Lemos, P.A., et al.
Catheter Cardiovasc Interv, 2009. **74**(5): p. 665-73.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19670303
63. *Comparing long-term outcomes between drug-eluting and bare-metal stents in the treatment of cardiac allograft vasculopathy*
Nfor, T., et al.
Catheter Cardiovasc Interv, 2009. **74**(4): p. 543-9.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19405161
64. *Multivessel drug-eluting stenting and impact of diabetes mellitus--a report from the EVENT registry*
Novack, V., et al.
Catheter Cardiovasc Interv, 2009. **73**(7): p. 874-80.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19180665
65. *A comparison of the mechanical performance characteristics of seven drug-eluting stent systems*
Schmidt, W., et al.
Catheter Cardiovasc Interv, 2009. **73**(3): p. 350-60.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19085917
66. *Early and long-term results of percutaneous coronary intervention for unprotected left main trifurcation disease*
Sheiban, I., et al.
Catheter Cardiovasc Interv, 2009. **73**(1): p. 25-31.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19089932
67. *Very long-term results comparing a simple versus a complex stenting strategy in the treatment of coronary bifurcation lesions*
Sheiban, I., et al.
Catheter Cardiovasc Interv, 2009. **74**(2): p. 313-20.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19496110

68. *Strategies for drug-eluting stent treatment of bifurcation coronary artery disease in the United States: insights from the e-Cypher S.T.L.L.R. trial*

Suzuki, N., et al.

Catheter Cardiovasc Interv, 2009. **73**(7): p. 890-7.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19455662

69. *Long-term clinical outcomes after drug-eluting stent implantation in unprotected left main coronary artery disease*

Tamburino, C., et al.

Catheter Cardiovasc Interv, 2009. **73**(3): p. 291-8.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19214963

70. *Real world safety and efficacy of the Janus Tacrolimus-Eluting stent: long-term clinical outcome and angiographic findings from the Tacrolimus-Eluting STent (TEST) registry*

Tamburino, C., et al.

Catheter Cardiovasc Interv, 2009. **73**(2): p. 243-8.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19156896

71. *PCI versus CABG for multivessel coronary disease in diabetics*

Tarantini, G., et al.

Catheter Cardiovasc Interv, 2009. **73**(1): p. 50-8.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19089938

72. *The paclitaxel-eluting Coroflex Please stent study (PECOPS I): the 3-year clinical follow-up*

Unverdorben, M., et al.

Catheter Cardiovasc Interv, 2009. **74**(5): p. 674-82.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19530156

73. *Long-term clinical and angiographic outcomes after implantation of sirolimus-eluting stents with a "modified mini-crush" technique in coronary*

bifurcation lesions

Yang, H.M., et al.

Catheter Cardiovasc Interv, 2009. **74**(1): p. 76-84.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19360861

74. *Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the Acute Catheterization and Urgent Intervention Triage Strategy trial*

Aoki, J., et al.

Circulation, 2009. **119**(5): p. 687-98.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19171852

75. *Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention*

Chen, K.Y., et al.

Circulation, 2009. **119**(25): p. 3207-14.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19528339

76. *Randomized study of the crush technique versus provisional side-branch stenting in true coronary bifurcations: the CACTUS (Coronary Bifurcations: Application of the Crushing Technique Using Sirolimus-Eluting Stents) Study*

Colombo, A., et al.

Circulation, 2009. **119**(1): p. 71-8.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19103990

77. *Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis*

Cook, S., et al.

Circulation, 2009. **120**(5): p. 391-9.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19620501

78. *Long-Term outcome of drug-eluting stents compared with bare metal stents in ST-segment elevation myocardial infarction: results of the paclitaxel- or sirolimus-eluting stent versus bare metal stent in Primary Angioplasty (PASEO) Randomized Trial*

Di Lorenzo, E., et al.

Circulation, 2009. **120**(11): p. 964-72.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19720939

79. *Sirolimus-eluting stent treatment at high-volume centers confers lower mortality at 6-month follow-up: results from the prospective multicenter German Cypher Registry*

Khattab, A.A., et al.

Circulation, 2009. **120**(7): p. 600-6.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19652087

80. *Long-term safety and effectiveness of unprotected left main coronary stenting with drug-eluting stents compared with bare-metal stents*

Kim, Y.H., et al.

Circulation, 2009. **120**(5): p. 400-7.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19620506

81. *Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation*

Kimura, T., et al.

Circulation, 2009. **119**(7): p. 987-95.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19204304

82. *Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies*

Kirtane, A.J., et al.

Circulation, 2009. **119**(25): p. 3198-206.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19528338

83. *Comparison of drug-eluting stents and coronary artery bypass surgery for the treatment of multivessel coronary disease: three-year follow-up results from a single institution*

Li, Y., et al.

Circulation, 2009. **119**(15): p. 2040-50.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19349321

84. *Volumetric intravascular ultrasound analysis of Paclitaxel-eluting and bare metal stents in acute myocardial infarction: the harmonizing outcomes with revascularization and stents in acute myocardial infarction intravascular ultrasound substudy*
Maehara, A., et al.
Circulation, 2009. **120**(19): p. 1875-82.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19858413
85. *Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up*
Marcucci, R., et al.
Circulation, 2009. **119**(2): p. 237-42.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19118249
86. *High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease*
Migliorini, A., et al.
Circulation, 2009. **120**(22): p. 2214-21.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19917884
87. *C-reactive protein and the risk of stent thrombosis and cardiovascular events after drug-eluting stent implantation*
Park, D.W., et al.
Circulation, 2009. **120**(20): p. 1987-95.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19884467
88. *Comparison of plaque sealing with paclitaxel-eluting stents versus medical therapy for the treatment of moderate nonsignificant saphenous vein graft lesions: the moderate vein graft lesion stenting with the taxus stent and intravascular ultrasound (VELETI) pilot trial*
Rodes-Cabau, J., et al.
Circulation, 2009. **120**(20): p. 1978-86.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19884468

89. *Temporal changes in coronary revascularization procedures, outcomes, and costs in the bare-metal stent and drug-eluting stent eras: results from the US Medicare program*
Ryan, J., et al.
Circulation, 2009. **119**(7): p. 952-61.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19204307
90. *Final 5-year results of the TAXUS II trial: a randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for de novo coronary artery lesions*
Silber, S., et al.
Circulation, 2009. **120**(15): p. 1498-504.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19786634
91. *Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial*
Stone, G.W., et al.
Circulation, 2009. **119**(5): p. 680-6.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19171853
92. *Three-year outcomes after sirolimus-eluting stent implantation for unprotected left main coronary artery disease: insights from the j-Cypher registry*
Toyofuku, M., et al.
Circulation, 2009. **120**(19): p. 1866-74.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19858414
93. *Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis*
Unverdorben, M., et al.
Circulation, 2009. **119**(23): p. 2986-94.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19487593
94. *Unprotected left main stenting in the real world: two-year outcomes of the French*

left main taxus registry

Vaquerizo, B., et al.

Circulation, 2009. **119**(17): p. 2349-56.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19380624

95. *A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents*

Byrne, R.A., et al.

Eur Heart J, 2009. **30**(8): p. 923-31.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19240066

96. *ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007*

Daemen, J., et al.

Eur Heart J, 2009. **30**(2): p. 152-61.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19036745

97. *Drug eluting or bare metal stent for acute myocardial infarction: an issue of safety?*

Finn, A.V., et al.

Eur Heart J, 2009. **30**(15): p. 1828-30.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19515688

98. *Pre-intervention eosinophil cationic protein serum levels predict clinical outcomes following implantation of drug-eluting stents*

Niccoli, G., et al.

Eur Heart J, 2009. **30**(11): p. 1340-7.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19383735

99. *MAHOROBA, first-in-man study: 6-month results of a biodegradable polymer sustained release tacrolimus-eluting stent in de novo coronary stenoses*

Onuma, Y., et al.

Eur Heart J, 2009. **30**(12): p. 1477-85.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19406868

100. *Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET*
Pfisterer, M., et al.
Eur Heart J, 2009. **30**(1): p. 16-24.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19033260
101. *Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events*
Steg, P.G., et al.
Eur Heart J, 2009. **30**(3): p. 321-9.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19147604
102. *Distribution of angiographic measures of restenosis after drug-eluting stent implantation*
Byrne, R.A., et al.
Heart, 2009. **95**(19): p. 1572-8.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19482849
103. *Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results*
Byrne, R.A., et al.
Heart, 2009. **95**(18): p. 1489-94.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19592388
104. *Dual antiplatelet therapy for more than 12 months after percutaneous coronary intervention: insights from the Guthrie PCI Registry*
Harjai, K.J., et al.
Heart, 2009. **95**(19): p. 1579-86.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19549619
105. *Comparison of inflammatory markers and angiographic outcomes after implantation of sirolimus and paclitaxel-eluting stents*
Kang, W.C., et al.
Heart, 2009. **95**(12): p. 970-5.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18772180

106. *Optical coherence tomography evaluation of zotarolimus-eluting stents at 9-month follow-up: comparison with sirolimus-eluting stents*

Kim, J.S., et al.

Heart, 2009. **95**(23): p. 1907-12.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19535352

107. *Sirolimus-eluting stents, bare metal stents or coronary artery bypass grafting for patients with multivessel disease including involvement of the proximal left anterior descending artery: analysis of the Arterial Revascularization Therapies study part 2 (ARTS-II)*

Kukreja, N., et al.

Heart, 2009. **95**(13): p. 1061-6.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19304671

108. *Obesity and cardiovascular thrombotic events in patients undergoing percutaneous coronary intervention with drug-eluting stents*

Wang, Z.J., et al.

Heart, 2009. **95**(19): p. 1587-92.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19592387

109. *Coronary aneurysms after drug-eluting stent implantation: clinical, angiographic, and intravascular ultrasound findings*

Alfonso, F., et al.

J Am Coll Cardiol, 2009. **53**(22): p. 2053-60.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19477355

110. *A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial*

Brilakis, E.S., et al.

J Am Coll Cardiol, 2009. **53**(11): p. 919-28.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19281920

111. *5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents*
Caixeta, A., et al.
J Am Coll Cardiol, 2009. **54**(10): p. 894-902.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19712798
112. *Outcome of drug-eluting versus bare-metal stenting used according to on- and off-label criteria*
Carlsson, J., et al.
J Am Coll Cardiol, 2009. **53**(16): p. 1389-98.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19371822
113. *Clinical effectiveness of coronary stents in elderly persons: results from 262,700 Medicare patients in the American College of Cardiology-National Cardiovascular Data Registry*
Douglas, P.S., et al.
J Am Coll Cardiol, 2009. **53**(18): p. 1629-41.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19406337
114. *Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Registry)*
Frobert, O., et al.
J Am Coll Cardiol, 2009. **53**(18): p. 1660-7.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19406341
115. *2-year clinical outcomes after implantation of sirolimus-eluting, paclitaxel-eluting, and bare-metal coronary stents: results from the WDHR (Western Denmark Heart Registry)*
Kaltoft, A., et al.
J Am Coll Cardiol, 2009. **53**(8): p. 658-64.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19232897
116. *A prospective, randomized, 6-month comparison of the coronary vasomotor*

response associated with a zotarolimus- versus a sirolimus-eluting stent: differential recovery of coronary endothelial dysfunction

Kim, J.W., et al.

J Am Coll Cardiol, 2009. **53**(18): p. 1653-9.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19406340

117. *Safety and effectiveness of drug-eluting and bare-metal stents for patients with off- and on-label indications*

Ko, D.T., et al.

J Am Coll Cardiol, 2009. **53**(19): p. 1773-82.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19422984

118. *Long-term clinical outcomes of sirolimus- versus paclitaxel-eluting stents for patients with unprotected left main coronary artery disease: analysis of the MAIN-COMPARE (revascularization for unprotected left main coronary artery stenosis: comparison of percutaneous coronary angioplasty versus surgical revascularization) registry*

Lee, J.Y., et al.

J Am Coll Cardiol, 2009. **54**(9): p. 853-9.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19695467

119. *Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease*

Mehilli, J., et al.

J Am Coll Cardiol, 2009. **53**(19): p. 1760-8.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19422982

120. *The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) registry*

Onuma, Y., et al.

J Am Coll Cardiol, 2009. **54**(3): p. 269-76.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19589442

121. *Sirolimus and everolimus induce endothelial cellular senescence via sirtuin 1 down-regulation: therapeutic implication of cilostazol after drug-eluting stent implantation*

Ota, H., et al.

J Am Coll Cardiol, 2009. **53**(24): p. 2298-305.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19520256

122. *Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents 70 restenotic cases from a cohort of 718 patients: FAILS (Failure in Left Main Study)*

Sheiban, I., et al.

J Am Coll Cardiol, 2009. **54**(13): p. 1131-6.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19761932

123. *Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis*

Sibbing, D., et al.

J Am Coll Cardiol, 2009. **53**(10): p. 849-56.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19264241

124. *Randomized comparison of minimally invasive direct coronary artery bypass surgery versus sirolimus-eluting stenting in isolated proximal left anterior descending coronary artery stenosis*

Thiele, H., et al.

J Am Coll Cardiol, 2009. **53**(25): p. 2324-31.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19539141

125. *Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry*

van Werkum, J.W., et al.

J Am Coll Cardiol, 2009. **53**(16): p. 1399-409.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19371823

126. *9-month clinical, angiographic, and intravascular ultrasound results of a prospective evaluation of the Axxess self-expanding biolimus A9-eluting stent in coronary bifurcation lesions: the DIVERGE (Drug-Eluting Stent Intervention for Treating Side Branches Effectively) study*

Verheye, S., et al.

J Am Coll Cardiol, 2009. **53**(12): p. 1031-9.

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation>

n&list_uids=19298915

127. *Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial*

Weisz, G., et al.

J Am Coll Cardiol, 2009. **53**(17): p. 1488-97.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19389558

128. *A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods*

Serruys, P.W., et al.

Lancet, 2009. **373**(9667): p. 897-910.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19286089

129. *Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden*

James, S.K., et al.

N Engl J Med, 2009. **360**(19): p. 1933-45.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19420363

130. *CABG vs. stenting--clinical implications of the SYNTAX trial*

Lee, T.H., L.D. Hillis, and E.G. Nabel

N Engl J Med, 2009. **360**(8): p. e10.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19228613

131. *Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease*

Serruys, P.W., et al.

N Engl J Med, 2009. **360**(10): p. 961-72.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19228612

132. *Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction*

Stone, G.W., et al.

N Engl J Med, 2009. **360**(19): p. 1946-59.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19420364

133. *Fractional flow reserve versus angiography for guiding percutaneous coronary intervention*
Tonino, P.A., et al.
N Engl J Med, 2009. **360**(3): p. 213-24.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19144937
134. *Analysis of the long-term effects of drug-eluting stents on coronary arterial wall morphology as assessed by virtual histology intravascular ultrasound*
Kubo, T., et al.
Am Heart J, 2010. **159**(2): p. 271-7.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20152226
135. *Does "late catch-up" exist in drug-eluting stents: insights from a serial quantitative coronary angiography analysis of sirolimus versus paclitaxel-eluting stents*
Park, K.W., et al.
Am Heart J, 2010. **159**(3): p. 446-453 e3.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20211308
136. *Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial*
Rasmussen, K., et al.
Lancet, 2010.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20231034
137. *Long-term clinical outcomes with the next-generation Resolute Stent System: a report of the two-year follow-up from the RESOLUTE clinical trial*
Meredith, I.T., et al.
EuroIntervention, 2010. **5**(6): p. 692-7.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20142220
138. *The Paclitaxel-Eluting Coroflex Stent Study II (PECOPS II) Acute and 6-Month Clinical and Angiographic Follow-Up, 1-Year Clinical Follow-Up*
Wiemer, M., et al.

J Interv Cardiol, 2010.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20236209

139. *Paclitaxel-eluting versus sirolimus-eluting stents in diabetes mellitus: a report from the National Heart, Lung, and Blood Institute Dynamic Registry*

Wolf, W.M., et al.

Circ Cardiovasc Interv, 2010. **3**(1): p. 42-9.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20118153

140. *Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial*

Kedhi, E., et al.

Lancet, 2010. **375**(9710): p. 201-9.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20060578

141. *Two-year clinical outcome after abciximab-coated stent implantation in patients with coronary artery disease*

Kim, S.S., et al.

Circ J, 2010. **74**(3): p. 442-8.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20103970